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NesiritideEnd of life is an unfortunate but inevitable phase of the heart failure patients' journey. It is often preceded by a
stage in the progression of heart failure deﬁned as advanced heart failure, and characterised by poor quality of
life and frequent hospitalisations. In clinical practice, the efﬁcacy of treatments for advanced heart failure is
often assessed by parameters such as clinical status, haemodynamics, neurohormonal status, and echo/MRI indi-
ces. From the patients' perspective, however, quality-of-life-related parameters, such as functional capacity, ex-
ercise performance, psychological status, and frequency of re-hospitalisations, aremore signiﬁcant. The effects of
therapies and interventions on these parameters are, however, underrepresented in clinical trials targeted to as-
sess advanced heart failure treatment efﬁcacy, and data are overall scarce. This is possibly due to a non-universal
deﬁnition of the quality-of-life-related endpoints, and to the difﬁcult standardisation of the data collection. These
uncertainties also lead to difﬁculties in handling trade-off decisions between quality of life and survival by pa-
tients, families and healthcare providers. A panel of 34 experts in the ﬁeld of cardiology and intensive cardiac
care from 21 countries around the world convened for reviewing the existing data on quality-of-life in patients
with advanced heart failure, discussing and reaching a consensus on the validity and signiﬁcance of quality-of-
life assessment methods. Gaps in routine care and research, which should be addressed, were identiﬁed. Finally,
publisheddata on the effects of current i.v. vasoactive therapies such as inotropes, inodilators, and vasodilators on
quality-of-life in advanced heart failure patients were analysed.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Table 1
Current methods to assess the QoL in acute and chronic heart failure.
Acute heart failure
• Visual analogue scale
• Likert scale (both by patient or physician)
• Surrogate measures of dyspnoea index, BNP levels, lung function according to
peak expiratory ﬂow measures, and others.
Chronic heart failure
• Web-based possibilities to ask patients how they feel (questionnaires)
• Standard questionnaire: Minnesota living with heart failure (MLHF)
• Standard questionnaire: Kansas city cardiomyopathy questionnaire (KCCQ)
• 6 min walking test is also used as an indicator of QoL or quality of performance
• New York Heart Association functional class
• RAND-36 general health survey (computer-based, requires the patient to be able
to use the system)1. Introduction
Advanced heart failure (AdHF) is a malignant disease by nature [1]. It
is characterised by a debilitating late course, with increasingly frequent
hospitalisations and considerablemorbidity besides the obviousmortality
[2]. Heart failure affects quality of life (QoL) more profoundly than many
other chronic diseases [3]. Even thoughQoL is amajor concern, it appears
that clinical management as well as research efforts do not focus sufﬁ-
ciently on this aspect. There is no good universal understanding of QoL
in clinical practice [4]. Moreover, clinical trials often lack the assessment
of relevant parameters, let alone using them as endpoints. Methods
used are often subjective nonparametric measures either by patient or
treating physician. In AdHF, daily variation is high and challenging for sta-
tistical analysis. Changes in echocardiographic or laboratory parameters
indeed represent quantiﬁable outcomes, but they do not necessarily im-
prove the daily life of the study participants, which is related to variables
less easy to be quantiﬁed, such as self-care [5]. Also, QoL is by itself fre-
quently variable in heart failure patients experience sometimes for rea-
sons independent from the clinical conditions of the patient.
Treatment generally aims at reducing mortality, but longevity might
well be an overrated goal in the management of AdHF. If the patient has
to choose between prolongation of life and maintaining acceptable QoL,
the choice is not always obvious. For example, somepatientsmight decide
against the implantation of an implantable cardiac deﬁbrillator (ICD),
even though they know that this choice can shorten their survival [6, 7],
when sudden death is foreseen as themost desirable outcome. Also, deci-
sions can change over time, depending on the feelings of the patients and
their families. As yet, there is only little data to shed light on this trade-off.
Finally, when AdHF patients experience a decompensation and are
hospitalised they often receive, on top of the optimal treatment with
ACEi/ARB, β-blockers, and aldosterone-antagonist, some i.v. vasoactive
treatment, i.e. inotropes, inodilators, and vasodilators. There seems to
be scarce evidence on the effect of these i.v. treatments for hospitalised
AdHF patients on short- or long-term QoL.
A panel of 34 experts in the ﬁeld of cardiology, intensive care medi-
cine, and cardiovascular pharmacology from 21 countries (Austria,
Brazil, Colombia, Croatia, Czech Republic, Finland, Germany, Greece,
Hungary, Israel, Italy, Mexico, Norway, Poland, Portugal, Russia,
Slovenia, Spain, Sweden, Switzerland, and Ukraine) convened in
Munich on January 23, 2015 for reviewing the existing data on QoL in
patients with AdHF, and for discussing and reaching a consensus on
the validity and signiﬁcance of QoL assessment methods. Gaps in
routine care and research, which should be addressed, were identiﬁed.
Finally, published data on the effect of non-pharmacologic and pharma-
cologic treatments on QoL in AdHF patients were analysed.2. Deﬁnition of QoL
QoL is not well deﬁned in chronic heart failure and even less so in
acute heart failure. None of the guidelines specify this outcome. Appar-
ently, some aspects such as depression and social function disability,
which are shown to have a signiﬁcant impact on health-related QoL in
patients with heart failure [8], are not taken into consideration to a satis-
fying degree. Other factors affecting QoL and functionality comprise per-
sistent congestion, neurohormonal/inﬂammatory activation, reduced
peripheral muscle blood ﬂow/myopathy, reduced kidney function, and
right ventricular dysfunction, along with severely compromised haemo-
dynamic state, which lead to cachexia. The inﬂammatory activation
present in heart failure has been shown to correlate with QoL [9]. More-
over, QoL decreases as New York Heart Association (NYHA) functional
class worsens [10]. Finally, exercise intolerance is a key factor.
Most of the available quality-of-life scores, such as the Minnesota
Living with Heart Failure Questionnaire (MLHFQ) and the Kansas City
Cardiomyopathy Questionnaire (KCCQ), are related to three major di-
mensions: physical, emotional, and social. Indeed, the data on available
treatments commonly relate to the effects of therapy on these dimen-
sions, but they are often rendered as the overall QoL scores without a
thorough discussion of the individual domains.
3. Assessment of QoL
Besides objective surrogate measurements, various subjective
methods can be used to assess the QoL in patients with heart failure, de-
pending onwhether their condition is acute or chronic (Table 1). A pilot
study suggests that health-related quality-of-life measures can be reli-
ably collected using internet-based software [11]. Data collected in
this manner are valid and of comparable quality to self-reported data
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ed. Assessment methods of QoL in acute and advanced chronic heart
failure vary because of the time-frame factor: e.g. short term ameliora-
tions in dyspnea are one of the typical parameters followed in patients
hospitalised for acute heart failure [12], while thewalking test is consid-
ered of importance in advanced heart failure patients.
3.1. QoL assessment in acute heart failure
While the visual analogue scale (VAS) offers absolute assessment of
symptoms such as dyspnoea (endpoint: AUC over 5 days), the Likert
scale focuses on relative assessment (endpoint: moderate/marked im-
provement at 6, 12, and 24 h) [13]. These scales have been used widely
in acute heart failure trials. However, beneﬁts conferred by the treat-
ment are often hard to demonstrate. A commendable approach might
be the inclusion of patients in studies early on, followed by monitoring
of their changes in dyspnoea over time.
In the acute setting, symptoms such as congestion and clinical as-
sessment of other heart failure signs are crucial, as they will also deﬁne
the patient's QoL after hospital discharge. There is a consensus that, after
hospital stay, patients should be followed up not only in terms of their
disease trajectory, but also concerning their QoL. Dyspnoea scores in
the acute phase and self-reported outcomes after one month of
discharge are recommended as the instruments of choice. In the acute
setting, dyspnoea is a compromisedmeasure as it is subjective andham-
pered by hospital environment, extra administration of oxygen, infec-
tions, poor lung function and even positioning of the patient in bed
rest. Dyspnoea scores as an index parameter should be evaluated as
early as possible during hospitalisation as a parametric measure of ther-
apeutic efﬁcacy.
Due to its signiﬁcance for adverse events and treatment compliance,
depression is an important aspect. However, there are no reliable tools
available to estimate depression in the acute phase. Many of the instru-
ments are based on self-rated questionnaires, while the diagnostic gold
standard is actually the interview with the specialist. Mental state is af-
fected by the degree of dyspnea, congestion and even hyponatremia,
when present [14].
3.2. QoL assessment in chronic heart failure
In a pivotal study assessing the impact of AdHF on QoL in 79 patients
hospitalised with HF in Sweden, patients were found to be signiﬁcantly
more affected by detrimental effects on sleep and energy than patients
with stroke, as measured with the Nottingham Health Proﬁle (NHP)
(Fig. 1) [15]. Both ESC and AHA highlighted the importance of patientMobility
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Fig. 1. QoL in patients with HF and stroke in the acute phase, measured by NHP (from
Franzén-Dahlin [15]). Higher scores indicate greater number and severity of problems
HF: heart failure; NHP: Nottingham Health Proﬁle; NS: not signiﬁcant; QoL: quality of
life. White bars: heart failure patients (n = 77); black bars: aphasic stroke patients
(n = 56).reported outcomes in heart failure by publishing recently two recom-
mendations at this regard [16, 17].
In chronic heart failure, the MLHFQ and the KCCQ are standard as-
sessment instruments, with the KCCQ being the most popular for use
in clinical studies. There are some differences between these two that
are elucidated in Table 2 [18].
The KCCQ, followed by the NYHA classiﬁcation and the 6-minute
walk test, was found to reﬂect clinical changes in patients with heart
failure most accurately [19]. Correlation coefﬁcients for social, function-
al and physical areas are higher with the KCCQ than with the MLHFQ.
Moreover, a more precise correlation of the KCCQ with survival has
been established [9].
These scores have some limitations, however. For instance, reduced
functional capacity is not sufﬁciently covered by the KCCQ. The NYHA
classiﬁcation might also be less than optimal, because it was developed
in 1970s in patients that differed from today's typical population.
Apart from questionnaires, when surrogate measures are called for,
exercise capacity can be evaluated by the use of the 6-minute walk
test or the cardiopulmonary exercise test. The latter is more accurate
and reproducible than the 6-minute walk test, but less practical for ev-
eryday use. Finally, psychological distress is a high risk in this vulnerable
patient group [20]. A holistic test that explores the physical, psycholog-
ical and social aspects alike is the assessment of the patient's sexual
satisfaction [21].
4. Rehospitalisation
While mortality neither reﬂects disease burden nor disease progres-
sion, because heart failure progresses stepwise, rehospitalisation rate is
a comprehensive measure of these outcomes. The length of hospital
stays has generally decreased over time in heart failure patients, but re-
admission rates have essentially remained unchanged [22]. After dis-
charge, approximately 50% of all patients are readmitted within six
months. Re-hospitalisation within 30 days occurs in 25% of cases. The
readmission rate increases from initial discharge to death with a high
ratio of preventable readmissions in the initial phase [23]. As Fig. 2
shows, the risk for readmission is highest immediately following dis-
charge and just before death.
4.1. Rehospitalisation as a measure of QoL
Congestion is the most frequent cause of readmission. Other factors
associated with increased risk of readmission include higher age, co-
morbidities, premature discharge and noncompliance. Hospitalisation
satisﬁes the demands of true surrogate endpoints, but it is also an end-
point in itself. It is easy to identify and easy to quantify. Time to ﬁrst
hospitalisation, frequency of hospitalisations, and duration of hospital
admissions can be assessed. Another dimension that matters from the
patient's point of view could be the number of days out of hospital as
a possible interpretation of QoL.Table 2
Comparison between the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
and the Kansas City Cardiomyopathy Questionnaire (KCCQ).
From Rector [18].
MLHFQ KCCQ
Self-administered Self-administered
21 items 23 items
Chronic heart failure-related physical,
emotional and social aspects
Functional score: physical activity and
symptoms
Summary score: functional score plus QoL
Speciﬁc dimensions: “self-efﬁcacy” &
“social limitation”
Each question, 6 point Likert scale Each question, 5–7 point Likert scale
Total range, 0–105 Total range, 0–100
The higher, the worse The higher, the better
Median Time from hospital discharge
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Fig. 2. Lifetime readmission risk after heart failure hospitalisation. Dark grey areas: highest risk for readmission; striped areas: lower risk, plateau phase; light grey area: assumed baseline
of inevitable readmissions.
From Desai & Stevenson [23].
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signiﬁcant increases in heart-failure-related health costs. With each re-
admission, QoL declines [24]. However, the established questionnaires
of QoL hardly assess hospitalisation frequency.
4.2. Rehospitalisation as a measure of quality of care
At the same time, readmissions can be perceived as a parameter of
quality of care. Hospitals frequently fail to implement strategies com-
monly recommended to reduce rehospitalisation [25]. Heart failure ad-
mission rates were demonstrated to vary considerably between
institutions [26]. Readmission, however, is not necessarily a sign of fail-
ure, as higher rates could be a consequence of successful care. Patients
who die during their index episodes can, in fact, never be readmitted
[27]. Also, some elective readmissions for enhancement of medical
care or interventions, including implantable device therapies, may rep-
resent appropriate care that reduces mortality.
4.3. HF management programmes
Improved outcomes have been achieved in outpatients discharged
from the emergency department with early collaborative care (care
provided by a primary care physician and a cardiologist) [28]. Patient
management in multidisciplinary heart failure treatment centres that
includes remote monitoring and self-treatment at home is deemed ca-
pable of lowering readmission rates [23]. As rehospitalisation often oc-
curs early, the panel feels that re-evaluation of the patient by the
heart failure nursing staff or the treating physicians in the ﬁrst two
weeks after discharge would be important.
Several strategies are associated with lower risk-standardised
30-day readmission rates (RSRR): [29]
• Partnering with community physicians or physician groups to reduce
readmission;
• Partnering with local hospitals to reduce readmissions;
• Having nurses responsible for medication reconciliation;
• Arranging follow-up appointments before discharge;• Having a process in place to send all discharge papers or electronic
summaries directly to the patient's primary physician;
• Assigning staff to follow up on test results that return after the patient
is discharged.
The number of selected strategies implemented was found to corre-
late with the RSRR.
5. The role of therapy in the improvement of QoL
Treatment goals naturally differ according to the setting. In acute
heart failure, survival is considered predominant over QoL due to the ir-
reversibility of death. In this line, the panel feels that more efﬁcacious
interventions for decongestion and improvement of haemodynamic
measures are needed, as the hospitalisation rates remain high. Howev-
er, even in the acute setting, several aspects of QoL, such as depression,
deserve heightened attention and should not be neglected, as mental
state may be a signiﬁcant factor for treatment compliance. More re-
search is required on the effects of acute heart failure therapies on QoL.
Depression is certainly one of the most important factors determin-
ing QoL in heart failure patients [8]. Its prevalence in acute and chronic
heart failure is estimated at 35% to 60% and 11% to 25%, respectively
[30]. An OPTIMIZE-HF analysis revealed that history of depression is a
predictor of length of hospital stay and post-discharge mortality [31].
Previous studies have suggested that their use can be associated
with an increased likelihood of death and cardiovascular hospitalisation
due to adverse pharmacodynamics effects [32]. Because depression has
also been shown to be associated with increased mortality in these pa-
tients, it remains unclear if this association is due to the use of antide-
pressants or to depression [33].
Special attention regarding the quality-of-life issues is required in
the “palliative setting”. Palliative care is by deﬁnition meant for malig-
nant states with known short life expectancy. It is commendable in
AdHF patients to prefer the term of “end-of-life” care. As opposed to
the management of cancer patients, the length of this stage is hard to
predict in the heart failure setting, particularly with current traditional
260 M.S. Nieminen et al. / International Journal of Cardiology 191 (2015) 256–264HF classiﬁcations by NYHA classiﬁcation and the ACC/AHA staging. In
fact, conventional nosology for the staging of heart failure has a number
of limitations, among which the inaccuracy in predicting the “end-of-
life” heart failure stages [34]. As well known, heart failure per se is not
conﬁned to the heart, but it is amultiple-organ disease [35]. A new stag-
ing system for heart failure, named HLM, has been proposed [36, 37],
which could be useful in assessing the true “end-of-life” stage heart fail-
ure patients in order to apply palliative care and to enhance QoL of these
individuals.
We should be more accurate in identifying HF patients with signs
of multi organ failure in the early phase of the disease, during re-
hospitalisations and during outpatients follow-up. Early organ protec-
tion and organ support in AdHF (liver, kidney, central nervous system)
is of the outmost importance for early and/or more appropriate treat-
ment or for identifying patients needing cyclic hospital treatment to im-
prove HF condition and QoL.
6. Pharmacological therapy
Medical treatment aiming at improving haemodynamic and QoL-
related outcomes such as congestion, cardiac output, cardiac index,
right ventricular failure in hospitalised AdHF patients are described in
the literature. When AdHF patients experience a decompensation and
are hospitalised they often receive, on top of the optimal treatment
with ACEi/ARB, β-blockers, and aldosterone-antagonist, some i.v. vaso-
active treatment, i.e. inotropes, inodilators, and vasodilators. According
to the AHA/ACC guidelines [38], inotropes and vasodilators are viable
pharmacological options for advanced chronic heart failure. The effects
of intermittent or repetitive doses of inotropes, vasodilators and
inodilators in AdHF patients have been described, both for a mere palli-
ative aim and also as a bridge to transplant. Their effects on surrogate
endpoints related to QoL have been also described, albeit with big
gaps for important parameters such as depression (Table 3).We hereby
review the documented effects of established inotropes, inodilators, and
vasodilators on QoL-related parameters in AdHF patients.
6.1. Dobutamine
Dobutamine has been used in chronic or repetitive fashion on pa-
tients with AdHF [42]. However, it was documented that dobutamine
causes tachyphylaxis [43], and its use in heart failure has been associat-
ed with increased mortality [44]. In a comparison of dobutamine-based
and milrinone-based therapy for advanced decompensated congestive
heart failure, dobutamine was considered more attractive also due to a
better economic impact [45].Table 3
Effects of inotropic and vasoactive therapies currently used in clinical practice on outcomes in
Hemodynamics Neuro-hormons QoL
Cardiac index Congestion/PCWP Dysp
Dobutamine ↑↑ ↓ ↓ ↓
Milrinone ↑↑ ↓↓ ↔ ↓
Levosimendan ↑↑ ↓↓ ↓ ↓
Nitroprusside ↑a ↓↓ ↓ ↓
Nesiritide ↑a ↓↓ ↓ ↓
n.d. = no relevant data obtained by cross-searching PubMed for (“parameter” and “active com
a Indirect effect.
b According to Fedele et al. [64].
c According to Lewis et al. [39].
d According to Mullens et al. [40].
e According to O'Connor et al. [41].
f According to Parissis et al. [52].
g According to Capomolla et al. [42] (vs. nitroprusside).
h According to Packer et al. [48].
i According to the meta-analyses by Nieminen et al. [50] and Silvetti et al. [51].
j According to Reed et al. [68].6.2. Milrinone
Continuous intravenousmilrinone therapy has been administered at
home in selected patients with advanced heart failurewho are listed for
transplant [46]. Some evidence was collected on the fact that this phos-
phodiesterase inhibitor reduces the number of hospitalisations and de-
creases the overall treatment costs of acute heart failure [47]. However,
despite its beneﬁcial haemodynamic actions, long-term therapy with
oralmilrinonewas shown to increase themorbidity andmortality of pa-
tientswith severe chronic heart failure [48]. Also the Prospective Trial of
Intravenous Milrinone for Exacerbations of Chronic Heart Failure
(OPTIME-CHF) study does not support the routine use of intravenous
milrinone as an adjunct to standard therapy in the treatment of patients
hospitalised for an exacerbation of chronic heart failure [49].
6.3. Levosimendan
Recent systematic reviews and meta-analyses reported that the cal-
cium sensitizer levosimendan conveys beneﬁts that are relevant for the
patient's QoL [50, 51]. In a study by Parissis et al., functional capacity and
scores of emotional stress favoured levosimendan over placebo [52].
Trials assessing the effects of repetitive administration have yielded im-
provements regarding functional capacity, left ventricular ejection frac-
tion, and quality-of-life scores [53–55]. Potential explanations for these
effects relate to levosimendan-mediated, sustained reductions in in-
ﬂammatory cytokines and apoptotic factors [56, 57]. Furthermore,
levosimendan treatment decreases oxidative stress, prevents oxidative
damage, and improves endothelial function as well as right ventricular
function [58–60]. Improving of right ventricular function is especially
important in AdHF with signs of right ventricular failure since ascites,
oedema and liver or kidney dysfunction have an important impact on
QoL. Brain natriuretic peptide (BNP) levels and inﬂammatory markers
are reduced in comparison to placebo [61]. In the REVIVE II trial an im-
provement in dyspnoea by levosimendan as compared to placebo was
shown [62]. In the LevoRep trial, the effects of repetitive levosimendan
infusions on 6-minute walk test, KCCQ clinical summary score, and
event-free survival were described [63] In a recent comparisonwith do-
butamine, levosimendan signiﬁcantly reduced re-hospitalisation rates
and shortened the length of hospital stay in acute heart failure by
1.5 days [64, 65].
6.4. Nitroprusside
Nitroprusside was shown to be more effective than dobutamine in
patients with end-stage heart failure awaiting heart transplantation
[42]. In patients with advanced, low-output heart failure, vasodilatoryAdHF patients.
-related parameters Survival
noea Rehospitali-zation rate Depression MLHFQ/KCCQ
↑b n.d. n.d. ↓g
↔c n.d. n. ↓h
↓b ↓f ↓f ↑b,i
↔d n.d. n. ↑c
↔e n.d. n. ↔j
pound”[ti]).
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current medical therapy during hospitalisation might be associated
with favourable long-term clinical outcomes [40].
6.5. Nesiritide
The effects of nesiritide on mortality and quality of life of AdHF pa-
tients were studied in the two FUSION clinical trials [66, 67], which
gave promising but not deﬁnitive answers, the authors warranting for
a deﬁnitive phase III mortality/quality of life trial. In the ASCEND-HF
trial, it did not signiﬁcantly inﬂuence medical resource use or health
utilities compared with standard care alone [68].
6.6. Drugs under development
Data on the effect on QoL parameters by the treatment of AdHF pa-
tients with vasodilators under clinical development such as carperitide,
serelaxin, and ularitide have been also published in the literature.
Carperitide was also used intermittently in outpatients with AdHF.
However, the experience is very limited here [69].
Serelaxin, a vasoactive peptide hormone, was shown to give rise to a
signiﬁcant but clinically small improvement in dyspnoea over placebo
according to the VAS scale, but not according to the Likert scale in the
RELAX-AHF trial [70]. The 180-day mortality was slightly but signiﬁ-
cantly reduced. A sub-analysis revealed that beneﬁts for both Likert
and VAS dyspnoea evaluation are seen in patients with preserved left
ventricular ejection fraction [71].
Ularitide, a synthetic natriuretic peptide hormone, is also capable of
improving dyspnoea and BNP levels [72]. A currently ongoing phase 3,
randomised, double-blind, placebo-controlled study in patients with
acute heart failure will provide additional 6 month morbidity and mor-
tality evidence.
7. Non-pharmacological therapy
Physical training is an important component of heart failure man-
agement, even if the severity of the disease creates limitation in the ad-
herence of patients to exercise programmes [73, 74].
Further, devices such as biventricular pacemakers for cardiac
resynchronisation therapy (CRT) andmitral clips for severemitral insuf-
ﬁciency could always be considered in appropriate heart failure pa-
tients. In fact, AdHF patients often experience atrial ﬁbrillation, which
necessitates expert care on heart rate control [75]. More recent ad-
vancements were reviewed elsewhere [76].
Although CRT-P that enhances QoL should be maintained, at the
end-of-life ICDs frequently deliver multiple shocks, which is a matter
of anxiety and poor QoL for patients and carers, and should be
deactivated [77, 78].
Further, tele-monitoring of patients discharged after heart failure
exacerbation is an important addition and was shown to be cost-
effective [79]. Finally, non-compliance with non-pharmacological rec-
ommendations in heart failure patients, was clearly associated with ad-
verse outcome [80].
8. Trade-off survival vs. QoL
Postponing death is a treatment goal apart from symptom relief.
Under certain circumstances, however, if life-prolonging measures are
expected to impair QoL, a choice has to bemade between these two. Re-
cently, Eschalier and co-workers tried to give an answer to the question
if there is any beneﬁt in optimising heart failure treatment in over-
80 year-old patients with their study HF-80 [81]. Several trials investi-
gated the topic of end-life-preferences in heart failure patients, with
conﬂicting results [7]. While preferences remained in favour of survival
for many patients despite AdHF symptoms in the study by Stevenson
et al. [82], Kraai et al. found that the majority of patients attach moreweight to QoL over longevity [6]. Another trial identiﬁed two distinct
groups of patients, one preferring treatments that prolonged survival
time and another that favoured strategies that improved QoL but re-
duced survival time [7]. These treatment preferenceswere independent
of functional or symptomatic status, suggesting that theymay be decid-
ed early in the course of illness. Formiga et al. stated that advance plan-
ning of end-of-life procedures and doctor–patient communication
regarding these items remain poor and must be improved [83]. Finally,
heart failure patients' own requests to forego resuscitation should be
considered. Dev et al. stated that these requests may reﬂect preferences
for intervention to enhance quality rather than prolong survival, which
is particularly important as these patients have high early mortality
[84].
9. Future research with focus on QoL
The inclusion of QoL or QoL-related parameters as clear primary
endpoint in future trials is strongly advocated. An important aspect
that should be elucidated is risk stratiﬁcation that allows for the ideal
timing of patient discharge from hospital in order to avoid early read-
mission. Also, validation of simple instruments such as the VAS would
be called for to facilitate their use in clinical practice. Up to date, there
are few but promising studies evaluating the safety and efﬁcacy of anti-
depressants in acute heart failure [85]. Future trials are also required to
assess the utility of treatments for depression and their safety proﬁles.
This is of growing importance considering the advancing average age
of heart failure patients, in whom drug–drug interactions and compli-
ance issues pose a challenge.
10. Conclusion
Heart failure adversely affects QoL, and its deterioration appears to
be related to poor long-termprognosis. QoL is inﬂuenced by amultitude
of factors derived from the physical, emotional and social situation of
the patient, which is why it cannot be categorised easily. Comprehen-
sive team approaches are of uppermost priority for many patients and
their relatives/caregivers, particularly in the end-of-life setting.
It appears that the available instruments of assessment require re-
ﬁnement with the aim of greater practicability in daily routine. Also,
QoL is frequently missing as an endpoint in clinical studies on AdHF pa-
tients, even though it doubtlessly offers merits as a measure of efﬁcacy
of treatment.
An issuewhich has not been debatedwell enough in the literature or
in the clinical societies is the trade-off of survival vs QoL. It still seems a
taboo to admit that very often this is amatter of choice for patients, fam-
ilies, and doctors, and that survival is not the clear answer [6, 7]. It re-
mains therefore puzzling that demonstrating advantages on long term
survival for new drugs to be used in the acute phase of AdHF is still a re-
quirement in regulatory clinical trials, while improvement of QoL are
not.
However, we are comforted by a recent report by Pani and co-
workers [86] wheremethods are advocated for the validation of patient
reported outcomes and measurements of well-being. We agree also
with those authors that the evaluation of ‘real-life’ treatment effective-
ness and of health as a value would help in the development of drugs
which take into account the “patient-perspective”.
In hospital drug therapy as well as non-pharmacological out-of-
hospital strategies should be adjusted according to QoL goals. In this
way it should be possible to also prevent unplanned frequent
readmissions, which are a common burden in the end-of-live stage of
patients with AdHF. Finally, the panel went through the sparse and con-
troversial evidence on the effects on QoL of i.v. inotropes and vasodila-
tors used during hospitalisation of AdHF patients. Among the drugs
already used in clinical practice, encouraging advantages were reported
in the literature for the inodilator levosimendan. Promising vasodilators
such as serelaxin and ularitide could also prove useful in the near future.
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